Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Dose Escalation/Expansion Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NCT04913337 is registered in ClinicalTrials.gov with NGM Biopharmaceuticals, Inc as lead sponsor.

NCT NCT04913337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04913337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Dose Escalation/Expansion Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Lead sponsor
NGM Biopharmaceuticals, Inc
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 9, 2021
Completion date
July 31, 2025
Enrollment
179 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cervical cancer, cholangiocarcinoma, colorectal cancer, endocervical cancer, esophageal cancer, gastric cancer, glioblastoma, melanoma, mesothelioma, non small cell lung cancer, ovarian cancer, pancreatic ductal adenocarcinoma, renal cell carcinoma, squamous cell carcinoma of head and neck